I used to hate Stocks when I owned this stock because I did not want to believe but rest assured this company will never help the investor. Get out while you can, lucky I sold at 3.17 after 1-4 reverse split, which I sold for a loss. The CEO is a dirt bag!
Haha! Sierra is the worst in regard to a news outlet. Not trustworthy what so ever.
Success_Now Meetings In NYC With Pfizer (PFE) On Wednesday Ventures Sierra World Equity Review
Latest Projections: The Big Apple_Celsion (CLSN) Pipeline Drug ThermoDox Success_Now Meetings In NYC With Pfizer (PFE) On Wednesday Ventures Sierra World Equity Review.
I believe that PFE and CLSN will be meeting in NYC this coming Wednesday. PFE desperately is looking for acquisitions of small bio techs that have excellent pipeline drugs to replace the drugs that their patents are expiring on. PFE main revenue sources are dwindling as the patents fall off and they have not had great success getting their own pipeline drugs past the FDA.
Wouldn't you think that some company would offer to buy out Celsion for $5 a share ($100 million) or even $7.50 a share ($150 Million) with all of this potential upside?
tanakvu, you must be new here.
check out clsn history and current financial statements
CLSN doesn't have the cash to fund the upcoming R&D and studies.
So if NO DILUTION, where is the cash going to come from to accomplish those studies?
-Clinical findings for the entire cohort of Chinese patients with a single tumor regardless of size show an impressive OS benefit.
May lead to additional opportunities for registrational discussions with the CFDA in the relatively in near future.
Wild card here would be China approval, CEO indicated they would know more next Quarter CC.
Chest Wall "we’re totaling up of 41 refractory patients with greater than 50% clinical response rate and with five complete responses".
Recurrent Chest Wall- "These are patients who are post-hysterectomy, who have failed at least two lines of chemotherapy"
"and have failed radiation before entering our trial. They are out of treatment options".
RCW patients "quality of life. They (FDA) told us they would accept them as a registrational endpoint".
Quality of life improvement would likely mean TDox would gain approval for these patients.
Strength of RCW data in this indication incurred several investigators in Europe to approach us for European based study.
Most of the cost of the European trial will be covered by the EU.
All of this is not bad and is very impressive and promising for the near future!!
I'm glad I got out of this POS at 3.17, and I might add that was after a 1-4 split so that the company was more attractive to institutional investors. Where are we today? I hope they’ll fold cause I’ll never recover my money from them…